Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.41B P/E - EPS this Y -5.30% Ern Qtrly Grth -
Income -308.55M Forward P/E -51.23 EPS next Y 64.50% 50D Avg Chg -4.00%
Sales 291.49M PEG -0.09 EPS past 5Y - 200D Avg Chg 7.00%
Dividend N/A Price/Book 28.53 EPS next 5Y 187.90% 52W High Chg -20.00%
Recommedations 1.60 Quick Ratio 2.34 Shares Outstanding 48M 52W Low Chg 92.00%
Insider Own 16.84% ROA -28.23% Shares Float 35.77M Beta 1.26
Inst Own 86.00% ROE -161.69% Shares Shorted/Prior 7.67M/7.67M Price 73.26
Gross Margin 90.30% Profit Margin -105.85% Avg. Volume 917,962 Target Price 123.69
Oper. Margin -87.06% Earnings Date Nov 4 Volume 779,427 Change -5.26%
About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc. News
11/13/24 Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
11/13/24 Q3 2024 Axsome Therapeutics Inc Earnings Call
11/12/24 Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
11/12/24 Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains
11/12/24 Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/08/24 Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
11/05/24 Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
10/29/24 Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
10/19/24 3 Bargain Stocks to Buy in a Market That's Priced for Perfection
10/15/24 Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
09/29/24 1 Under-the-Radar Biotech Stock to Buy and Hold
09/24/24 Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
09/05/24 FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
09/04/24 Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
08/27/24 Axsome Therapeutics to Participate in Investor Conferences in September
06:00 AM Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
08/16/24 Jim Cramer Thinks Axsome Therapeutics Inc (NASDAQ:AXSM) Stock Can Double
08/05/24 Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
08/05/24 Why Axsome Therapeutics Stock Is Sinking Today
08/05/24 Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
AXSM Chatroom

User Image Mike826_1999 Posted - 13 hours ago

$AXSM New SEC form 4 filed: The form is filed for Mark Coleman, who is listed as an insider of Axsome Therapeutics, Inc. (AXSM). His role is not explicitly detailed in this filing but could be a director, officer, or significant shareholder. Transaction Details: Date: The transaction occurred on November 19, 2024. Transaction Code: "M" indicates the exercise of stock options to acquire shares. Securities Acquired or Disposed: 33,410 shares of common stock were acquired at an exercise price of $5.94 per share through stock options. After the transaction, Mark Coleman holds: 48,010 shares directly. 403,856 shares indirectly, managed through another entity. Stock Options: These options were exercised before their expiration on June 29, 2025. Significance: This reflects insider activity and could indicate confidence in the company's performance, as insiders often exercise options if they anticipate favorable stock price movements. https://axsometherapeuticsinc.gcs-web.com/static-files/d5d158f1-86b9-42ed-8f87-303e2ec9e11e

User Image RickSanders9 Posted - 13 hours ago

$AXSM https://www.patientcareonline.com/view/treatment-for-agitation-in-alzheimer-dementia-pipeline-preview-with-george-grossberg-md

User Image My_Lai_1968 Posted - 16 hours ago

$AXSM I have just sent an Emergency Alert to the NAACP, Mothers Against Drunk Drivers (MADD), ALL Manufacturers of Coin-Operated Laundry Machines, Obese Bridesmaids with Torn Wedding Dresses, Elementary Students with Peanut Allergies, Incarcerated Inmates with Sore Rectums, Women who are only 3 1/2 feet tall who have been deemed the "Perfect height" and Illegal Aliens selling counterfeit enchiladas to Buy shares of AXSM as it runs to $179 by January 4. Stay tuned until my further instructions.

User Image Mike826_1999 Posted - 16 hours ago

$AXSM I generally avoid shorting stocks due to the associated risks, but I'm curious if anyone here has experience both shorting and then going long on AXSM? Given its volatility, such strategies could prove to be profitable for those willing to take on the risk. For instance, if someone had the nerve to short AXSM at $105 and close at $92, then switch to a long position, it might have been quite profitable in hindsight, given the benefit of 20/20 vision. I asked the same on some other boards.

User Image RosaAtchison819 Posted - 17 hours ago

$AXSM With the launch of SARA, AITX is raising the bar and challenging the norms. Meanwhile, KSCP remains stuck with old methodologies, unable to compete. This dynamic shift is cementing AITX's place as a leader, while KSCP risks falling by the wayside.

User Image jeremytowe2000 Posted - 18 hours ago

$AXSM Thank you for those who got flushed out below $30. It helped me to load more and unfortunately my average went up little close to $10.50 for 87K shares. Well, I don't mind.

User Image noobzilla Posted - 19 hours ago

$AXSM Added more this morning for short term swing trade. I'm optimistic with the upcoming phase 3 results. I will definitely sell these new shares before end of year unless the results come out last day or two of trading 2024.

User Image Crimson_Phoenix Posted - 19 hours ago

$AXSM Moving up, at least, despite the volume being pffft!

User Image Mike826_1999 Posted - 19 hours ago

@xoxoxoxo1 $AXSM MS: Model updates bring our PT to $125. We update our model for the quarter and roll forward our DCF, which includes adjustments to our FY24 op. ex. assumptions. Additionally, following the stronger than anticipated quarter for Auvelity and the company’s announcement of a sales force expansion in 1Q25, we modestly increase our Auvelity MDD sales estimates and now forecast peak U.S. sales of ~$1.2B (vs. ~$1.0B previously). Net of these changes, our PT increases from $115 to $125. We maintain OW heading into the ADA data sets.

User Image jeremytowe2000 Posted - 20 hours ago

$AXSM $TGTX now one day closer than yesterday.

User Image FairfieldCapital Posted - 1 day ago

$AXSM If you’re reading this, you are on their list! Short Seller - Culper Research. Or one might say Culper Rubbish. Claiming Scams and shams, criminal activity, and too good to be true. All their words not mine. Some claim market manipulation and “trash and cash”. You be the judge. Let them know what you think. I’m sure they would love to hear from you. https://culperresearch.com/contact

User Image xoxoxoxo1 Posted - 1 day ago

$AXSM 🙌😎🌎👌🏼

User Image xoxoxoxo1 Posted - 1 day ago

$AXSM when does this hit $125? After trials info or next fda approval.. 150 plus after second approval or scripts doubling comp for Auvelity? No pump- this is going to happen. The $200 will be just as exciting as hitting $100 for the second time in company history with primary data points met back in 2019.

User Image This_Bull_Is_Retired Posted - 1 day ago

$AXSM New to stock as of 10.12.24. Could this be a potential BO Target?

User Image cadbrad1 Posted - 1 day ago

$AXSM Looks like something is brewing…

User Image noobzilla Posted - 1 day ago

$AXSM about to take off? Come on fund transfer, go faster! I don't want to get left behind!

User Image Crimson_Phoenix Posted - 1 day ago

$AXSM a couple of notes about AXSM here on my Fidelity Analytics board: Over the past 30 minutes, AXSM is outperforming the Russell 2000 2:02 pm ET AXSM is trading above its normal trading range 2:02 pm ET

User Image jozef56 Posted - 1 day ago

$AXSM after a good earnings rapport within 1 week from €104 (intraday) to € 92. This is an 11.5% decrease on no significant news. This shows how much manupilators on this stock are active. One has to stand his grond to not become a victim on bad timed swing trades.

User Image jeremytowe2000 Posted - 1 day ago

$AXSM God knows who can win the race of being most silent person on the earth. HT or Biden ??

User Image JayC_Epic Posted - 1 day ago

$AXSM

User Image xoxoxoxo1 Posted - 2 days ago

$AXSM time for a silly mai lai story! Where is he when we need him. This board is getting bored!! 😴

User Image xoxoxoxo1 Posted - 2 days ago

$AXSM shorts having fun. Any word on when trial results will be released? Nice pop after earnings report was a nice change for what they usually produce. Tutes waiting patiently before the next leg up…

User Image Mike826_1999 Posted - 2 days ago

$AXSM State-of-the-science webinar will explore narcolepsy and hypersomnia https://www.prweb.com/releases/state-of-the-science-webinar-will-explore-narcolepsy-and-hypersomnia-302308786.html

User Image SirSorin Posted - 2 days ago

$AXSM will it ever break 100-110? Lost the AI boom having my money traped on this stock, with good results and promising news went to 100 them quickly back. With good results on ADA will be back to 100+ them to 90 in matters of days. This is the best scenario when the results are good. Feel like i'll never get payed for all the time and money i've invested on this. Can't wait 31st of Jan for FDA then i want to forget this company

User Image Willdowdell Posted - 2 days ago

$AXSM continued RFK effect , way too fringe, no science background

User Image jlfromli Posted - 2 days ago

$AXSM Doubled up Here In for a 2k swing!

User Image forprofit12 Posted - 2 days ago

$AXSM what’s with the love for 94? Took ages to break through only to get back to it

User Image noobzilla Posted - 2 days ago

$AXSM debating whether to take out loans at 9% APR to add more here

User Image PDDiddy Posted - 2 days ago

$AXSM buying more. too many kids with autism these days. GOLDMINE

User Image quickaspeter Posted - 3 days ago

$AXSM Let’s go!!!

Analyst Ratings
Cantor Fitzgerald Overweight Sep 20, 24
Cantor Fitzgerald Overweight Sep 16, 24
Cantor Fitzgerald Overweight Sep 9, 24
Cantor Fitzgerald Overweight Sep 6, 24
HC Wainwright & Co. Buy Sep 5, 24
Needham Buy Sep 5, 24
Wells Fargo Overweight Sep 3, 24
HC Wainwright & Co. Buy Aug 22, 24
UBS Buy Aug 6, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Coleman Mark Director Director Sep 15 Sell 75.18 29,588 2,224,426 403,856 09/15/23
Coleman Mark Director Director Sep 15 Option 3.67 11,016 40,429 36,113 09/15/23
Coleman Mark Director Director Mar 15 Option 1.30 3,496 4,545 7,596 03/17/22